Emerging pharmacological agents to improve survival from traumatic brain injury

References

• Guidelines for the management of severe traumatic brain injury. Journal of Neurotrauma 2007;24:S1–106
   Google Scholar
• Greve MW, Zink BJ. Pathophysiology of traumatic brain injury. Mt Sinai Journal of Medicine 2009;76:97–104
   PubMed Web of Science ®Google Scholar
• McConeghy KW, Hatton J, Hughes L, Cook AM. A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury. CNS Drugs 2012;26:613–636
   PubMed Web of Science ®Google Scholar
• Erdman J, Oria M, Pillsbury L, editors. Nutrition and traumatic brain injury: improving acute and subacute health outcomes in military personnel. Washington, DC: Institute of Medicine; The National Academies Press; 2011
   Google Scholar
• Tran TY, Dunne IE, German JW. Beta blockers exposure and traumatic brain injury: A literature review. Neurosurg Focus 2008;25:E8
   PubMed Web of Science ®Google Scholar
• Cotton BA, Snodgrass KB, Fleming SB, Carpenter RO, Kemp CD, Arbogast PG, Morris JA Jr. Beta-blocker exposure is associated with improved survival after severe traumatic brain injury. Journal of Trauma 2007;62:26–33
   PubMed Web of Science ®Google Scholar
• Inaba K, Teixeira PG, David JS, Chan LS, Salim A, Brown C, Browder T, Beale E, Rhee P, Demetriades D. Beta-blockers in isolated blunt head injury. Journal of the American College of Surgeons 2008;206:432–438
   PubMed Web of Science ®Google Scholar
• Bukur M, Mosheni S, Ley E, Salim A, Margulies D, Talving P, Demetriades D, Inaba K. Efficacy of beta-blockade after isolated blunt head injury: Does race matter? Journal of Trauma and Acute Care Surgery 2012;72:1013–1018
   PubMed Web of Science ®Google Scholar
• Schroeppel TJ, Fischer PE, Zarzaur BL, Magnotti LJ, Clement LP, Fabian TC, Croce MA. Beta-adrenergic blockade and traumatic brain injury: Protective? Journal of Trauma 2010;69:776–782
   PubMedGoogle Scholar
• Roberts I, Yates D, Sandercock P, Farrell B, Wasserberg J, Lomas G, Cottingham R, Svoboda P, Brayley N, Mazairac G, et al. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): Randomised placebo-controlled trial. Lancet 2004;364:1321–1328
   PubMed Web of Science ®Google Scholar
• Wible EF, Laskowitz DT. Statins in traumatic brain injury. Neurotherapeutics 2010;7:62–73
   PubMed Web of Science ®Google Scholar
• Tapia-Perez JH, Sanchez-Aguilar M, Torres-Corzo JG, Gordillo-Moscoso A, Martinez-Perez P, Madeville P, de la Cruz-Mendoza E, Chalita-Williams J. Effect of rosuvastatin on amnesia and disorientation after traumatic brain injury (NCT003229758). Journal of Neurotrauma 2008;25:1011–1017
   PubMed Web of Science ®Google Scholar
• Schneider EB, Efron DT, MacKenzie EJ, Rivara FP, Nathens AB, Jurkovich GJ. Premorbid statin use is associated with improved survival and functional outcomes in older head-injured individuals. Journal of Trauma 2011;71:815–819
   PubMedGoogle Scholar
• ClinicalTrials.gov. Effects of erythropoietin on cerebral vascular dysfunction and anemia in traumatic brain injury. Bethesda, MD: National Library of Medicine (US); Available online at: http://clinicaltrials.gov/ct2/results?term=NCT00313716, accessed 31 August 2012
   Google Scholar
• Mammis A, McIntosh TK, Maniker AH. Erythropoietin as a neuroprotective agent in traumatic brain injury Review. Surgical Neurology 2009;71:527–531
   PubMed Web of Science ®Google Scholar
• Nirula R, Diaz-Arrastia R, Brasel K, Weigelt JA, Waxman K. Safety and efficacy of erythropoietin in traumatic brain injury patients: A pilot randomized trial. Critical Care Research and Practice 2010;2010:1–5
   Google Scholar
• Talving P, Lustenberger T, Kobayashi L, Inaba K, Barmparas G, Schnuriger B, Lam L, Chan LS, Demetriades D. Erythropoiesis stimulating agent administration improves survival after severe traumatic brain injury: A matched case control study. Annals of Surgery 2010;251:1–4
   PubMed Web of Science ®Google Scholar
• Talving P, Lustenberger T, Inaba K, Lam L, Mohseni S, Chan L, Demetriades D. Erythropoiesis-stimulating agent administration and survival after severe traumatic brain injury: A prospective study. Archives of Surgery 2012;147:251–255
   PubMedGoogle Scholar
• Napolitano LM, Fabian TC, Kelly KM, Bailey JA, Block EF, Langholff W, Enny C, Corwin HL. Improved survival of critically ill trauma patients treated with recombinant human erythropoietin. Journal of Trauma 2008;65:285–297
   PubMed Web of Science ®Google Scholar
• Espinoza TR, Wright DW. The role of progesterone in traumatic brain injury. Journal of Head Trauma Rehabilitation 2011;26:497–499
   PubMed Web of Science ®Google Scholar
• Stein DG. Progesterone in the treatment of acute traumatic brain injury: A clinical perspective and update. Neuroscience 2011;191:101–106
   PubMed Web of Science ®Google Scholar
• Wright DW, Kellermann AL, Hertzberg VS, Clark PL, Frankel M, Goldstein FC, Salomone JP, Dent LL, Harris OA, Ander DS, et al. ProTECT: A randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine 2007;49:391–402
   PubMed Web of Science ®Google Scholar
• Xiao G, Wei J, Yan W, Wang W, Lu Z. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: A randomized controlled trial. Critical Care 2008;12:R61
   PubMed Web of Science ®Google Scholar
• Junpeng M, Huang S, Qin S. Progesterone for acute traumatic brain injury. Cochrane Database System Review 2011:1--25 , CD008409
   Web of Science ®Google Scholar
• Meythaler JM, Peduzzi JD, Eleftheriou E, Novack TA. Current concepts: Diffuse axonal injury-associated traumatic brain injury. Archives of Physical Medicine & Rehabilitation 2001;82(1):1461–1471
   PubMedGoogle Scholar
• Gualtieri T, Chandler M, Coons TB, Brown LT. Amantadine: A new clinical profile for traumatic brain injury. Clinical Neuropharmacology 1989;12:258–270
   PubMed Web of Science ®Google Scholar
• Sawyer E, Mauro LS, Ohlinger MJ. Amantadine enhancement of arousal and cognition after traumatic brain injury. Annals of Pharmacotherapy 2008;42:247–252
   PubMed Web of Science ®Google Scholar
• Giacino JT, Whyte J, Bagiella E, Kalmar K, Childs N, Khademi A, Eifert B, Long D, Katz DI, Cho S, et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. New England Journal of Medicine 2012;366:819–826
   PubMed Web of Science ®Google Scholar
• Firsching R, Piek J, Skalej M, Rohde V, Schmidt U, Striggow F. Early survival of comatose patients after severe traumatic brain injury with the dual cannabinoid CB1/CB2 receptor agonist KN38-7271: A randomized, double-blind, placebo-controlled phase II trial. Journal of Neurological Surgery Part A Central European Neurosurgery 2012;73:204–216
   PubMedGoogle Scholar
• Temkin NR, Anderson GD, Winn HR, Ellenbogen RG, Britz GW, Schuster J, Lucas T, Newell DW, Mansfield PN, Machamer JE, et al. Magnesium sulfate for neuroprotection after traumatic brain injury: A randomised controlled trial. Lancet Neurology 2007;6:29–38
   PubMed Web of Science ®Google Scholar
• Shakur H, Andrews P, Asser T, Balica L, Boeriu C, Quintero JD, Dewan Y, Druwe P, Fletcher O, Frost C, et al. The BRAIN TRIAL: A randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury. Trials 2009;10:109
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Early propranolol after traumatic brain injury: Phase II. Bethesda, MD: National Library of Medicine (US); Available online at: http://clinicaltrials.gov/ct2/results?term=NCT01202110, accessed 31 August 2012
   Google Scholar
• ClinicalTrials.gov. DASH After TBI study: Decreasing adrenergic or sympathetic hyperactivity after traumatic brain injury. Bethesda, MD: National Library of Medicine (US); Available online at: http://clinicaltrials.gov/ct2/results?term=NCT01322048, accessed 31 August 2012
   Google Scholar
• ClinicalTrials.gov. Mission connect mild traumatic brain injury (TBI) integrated clinical protocol. Bethesda, MD: National Library of Medicine (US); Available online at: http://clinicaltrials.gov/ct2/results?term=NCT01013870, accessed 31 August 2012
   Google Scholar
• ClinicalTrials.gov. Effect of rosuvastatin on cytokines after traumatic brain injury.Bethesda, MD: National Library of Medicine (US); Available online at: http://clinicaltrials.gov/ct2/results?term=NCT00990028, Accessed August 31, 2012
   Google Scholar
• ClinicalTrials.gov. Erythropoietin in traumatic brain injury (EPO-TBI). Bethesda, MD: National Library of Medicine (US); Available online at: http://clinicaltrials.gov/ct2/results?term=NCT00987454, accessed 31 August 2012
   Google Scholar
• ClinicalTrials.gov. Safety of darbepoetin alfa treatment in patients with severe traumatic brain injury. Bethesda, MD: National Library of Medicine (US); Available online at: http://clinicaltrials.gov/ct2/results?term=+NCT00375869, accessed 31 August 2012
   Google Scholar
• Watson Laboratories Inc. Progesterone (progesterone) package insert. Morristown, NJ: Watson Laboratories Inc.; 2012
   Google Scholar
• ClinicalTrials.gov. Progesterone for the treatment of traumatic brain injury (ProTECT III). Bethesda, MD: National Library of Medicine (US); Available online at: http://clinicaltrials.gov/ct2/results?term=NCT00822900, accessed 31 August 2012
   Google Scholar
• ClinicalTrials.gov. Efficacy and safety study of intravenous progesterone in patients with severe traumatic brain injury (SyNAPSe). Bethesda, MD: National Library of Medicine (US); Available online at: http://clinicaltrials.gov/ct2/results?term=NCT01143064, accessed 31 August 2012
   Google Scholar
• Cekic M, Stein DG. Traumatic brain injury and aging: Is a combination of progesterone and vitamin D hormone a simple solution to a complex problem? Neurotherapeutics 2010;7:81-90
   PubMed Web of Science ®Google Scholar